- Report
- May 2026
- 100 Pages
Global
From €2407EUR$2,699USD£2,065GBP
- Report
- April 2026
- 139 Pages
Global
From €2675EUR$2,999USD£2,294GBP
€3567EUR$3,999USD£3,059GBP
- Report
- February 2025
- 90 Pages
Global
From €5307EUR$5,950USD£4,552GBP
- Report
- January 2024
- 200 Pages
Global
From €3702EUR$4,150USD£3,175GBP
- Report
- September 2021
- 40 Pages
China
From €2319EUR$2,600USD£1,989GBP
Keppra is a brand name of the antiepileptic drug levetiracetam, which is used to treat epilepsy and other seizure disorders. It is a member of the Central Nervous System (CNS) drug class, which includes drugs used to treat neurological conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Keppra is approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial onset seizures in adults and children aged four years and older. It is also approved for the treatment of myoclonic seizures in adults and children aged 12 years and older.
Keppra is available in both oral and intravenous formulations. It is marketed by UCB, Inc., a biopharmaceutical company based in Belgium. Other companies that market levetiracetam include Mylan Pharmaceuticals, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more